|Title:||The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid||Authors:||Lee J.Y.
|Keywords:||Consensus; Contrast media; Liver; Pancreatobiliary; Sonazoid; Ultrasonography||Issue Date:||2020||Publisher:||Wolters Kluwer Medknow Publications||Journal Volume:||28||Journal Issue:||2||Start page/Pages:||59-82||Source:||Journal of Medical Ultrasound||Abstract:||
The first edition of the guidelines for the use of ultrasound contrast agents was published in 2004, dealing with liver applications. The second edition of the guidelines in 2008 reflected changes in the available contrast agents and updated the guidelines for the liver, as well as implementing some nonliver applications. The third edition of the contrast-enhanced ultrasound (CEUS) guidelines was the joint World Federation for Ultrasound in Medicine and Biology-European Federation of Societies for Ultrasound in Medicine and Biology (WFUMB-EFSUMB) venture in conjunction with other regional US societies such as Asian Federation of Societies for Ultrasound in Medicine and Biology, resulting in a simultaneous duplicate on liver CEUS in the official journals of both WFUMB and EFSUMB in 2013. However, no guidelines were described mainly for Sonazoid due to limited clinical experience only in Japan and Korea. The new proposed consensus statements and recommendations provide general advice on the use of Sonazoid and are intended to create standard protocols for the use and administration of Sonazoid in hepatic and pancreatobiliary applications in Asian patients and to improve patient management. ? 2019 Journal of Medical Ultrasound | Published by Wolters Kluwer - Medknow.
|ISSN:||0929-6441||DOI:||10.4103/JMU.JMU_124_19||SDG/Keyword:||alanine aminotransferase; albunex; aspartate aminotransferase; bilirubin; C reactive protein; echo contrast medium; echovist; perflexane; perflubutane; perfluoropentane; perflutren; quantison; shu 508; sonovist; sulfur hexafluoride; abdominal pain; ablation therapy; adverse event; alanine aminotransferase level; albuminuria; anaphylaxis; antiangiogenic therapy; arrival time parametric imaging; Article; Asian; aspartate aminotransferase level; B scan; backache; bile duct carcinoma; biliary sludge; bilirubin blood level; cavitation; chemoembolization; chill; consensus; contrast-enhanced ultrasound; diagnostic imaging; diarrhea; differential diagnosis; dizziness; drug excretion; dyspepsia; dysplastic nodule; dyspnea; echocardiography; echography; elimination half-life; endoscopic ultrasonography; falling; fatigue; fatty liver; flash imaging; follow up; gallbladder; gallstone; headache; hemodynamics; hepatic angiomyolipoma; hepatic artery; hepatic portal vein; hepatography; history; hot flush; human; hypotension; image analysis; image artifact; image display; image enhancement; indigestion; injection; injection site discomfort; laparotomy; liver abscess; liver adenoma; liver biopsy; liver carcinogenesis; liver cell carcinoma; liver cirrhosis; liver cyst; liver hemangioma; liver injury; liver metastasis; liver nodule; liver resection; liver tumor; liver vein; lymphoma; maximum concentration; microbubble; nausea; neutropenia; nodular hyperplasia; nuclear magnetic resonance imaging; oscillation; pancreas cyst; pancreatography; patient care; patient monitoring; percutaneous biopsy; perfusion parametric imaging; peroperative echography; pharmacokinetic parameters; plasma cell granuloma; pneumonia; portal vein thrombosis; postmarketing surveillance; practice guideline; proteinuria; pseudoenhancement artifact; pseudowash out artifact; radiofrequency ablation; rash; regenerative nodule; response evaluation criteria in solid tumors; safety; sensory dysfunction; shock; systemic therapy; three-dimensional imaging; treatment contraindication; treatment response; tumor ablation; urticaria; veiling artifact; weakness; x-ray computed tomography; xerostomia
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.